glp-1 medications approved for type 2 diabetes 2025 Top Obesity and Transforming U.S. Pharma Market GLP-1 Pipeline Update: February 2025

In this study we also used GWAS summary data from the GTExPortal ( and the IEU OpenGWAS project ( the data we used are publicly available summary statistics and can be obtained upon reasonable request

For many people, this is a small price to pay for avoiding needles entirely

GLP-1 drugs are a class of medications used to treat obesity and type 2 diabetes that include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)

This rapid turnover makes it unlikely that peripheral GLP-1 significantly contributes to endogenous activation of central GLP-1Rs

The key lies in proactive digestion management and tweaking dietary habits